ENDOCRINE TUMOURS: Approach to the patient with advanced differentiated thyroid cancer

RAF inhibition and induction of cutaneous squamous cell carcinoma

(2011) Caroline Robert et al.   CURRENT OPINION IN ONCOLOGY

Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population

(2011) Merina Ahmed et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Inhibition of the Ras/Raf/MEK/ERK and RET Kinase Pathways with the Combination of the Multikinase Inhibitor Sorafenib and the Farnesyltransferase Inhibitor Tipifarnib in Medullary and Differentiated Thyroid Malignancies

(2011) David S. Hong et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Phase II Study of Daily Sunitinib in FDG-PET-Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging Correlation

(2010) L. L. Carr et al.   CLINICAL CANCER RESEARCH

Cytotoxic Chemotherapy for Differentiated Thyroid Carcinoma

(2010) S.I. Sherman   CLINICAL ONCOLOGY

Sorafenib-Induced Hypothyroidism Is Associated with Increased Type 3 Deiodination

(2010) Randa M. Abdulrahman et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study

(2010) Keith C Bible et al.   LANCET ONCOLOGY

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

(2010) Poulikos I. Poulikakos et al.   NATURE

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma

(2009) Hendrieke Hoftijzer et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

RAS Mutations Are the Predominant Molecular Alteration in Poorly Differentiated Thyroid Carcinomas and Bear Prognostic Impact

(2009) Marco Volante et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Phase I Clinical Trials in 56 Patients with Thyroid Cancer: The M. D. Anderson Cancer Center Experience

(2009) Apostolia Maria Tsimberidou et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Phase II Trial of Sorafenib in Metastatic Thyroid Cancer

(2009) Richard T. Kloos et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical Trials for Progressive Differentiated Thyroid Cancer: Patient Selection, Study Design, and Recent Advances

(2009) Martin Schlumberger et al.   THYROID

The Successful Use of Sorafenib to Treat Pediatric Papillary Thyroid Carcinoma

(2009) Steven G. Waguespack et al.   THYROID

Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer

(2009) David S. Cooper et al.   THYROID

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Postoperative External Beam Radiotherapy for Differentiated Thyroid Cancer: Outcomes and Morbidity With Conformal Treatment

(2008) David L. Schwartz et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

BRAFV600EMutation Is Associated with Preferential Sensitivity to Mitogen-Activated Protein Kinase Kinase Inhibition in Thyroid Cancer Cell Lines

(2008) Rebecca Leboeuf et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study

(2008) Ezra E.W. Cohen et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Sorafenib in Advanced Thyroid Cancer

(2008) Vandana Gupta-Abramson et al.   JOURNAL OF CLINICAL ONCOLOGY

Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer

(2008) Steven I. Sherman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phosphatidylinositol 3-Kinase/Akt and Ras/Raf-Mitogen-Activated Protein Kinase Pathway Mutations in Anaplastic Thyroid Cancer

(2007) Libero Santarpia et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM